Your institution may have rights to this item. Sign in to continue.
Title
DAPA-HF: Baseline Kidney Function did not Modify the Benefits of Dapagliflozin on Morbidity & Mortality in HFrEF, and Dapagliflozin Slowed the Rate of Decline in eGFR, Including in Patients Without Diabetes.